Jazz Pharmaceuticals plc (NASDAQ:JAZZ – Get Rating) has been assigned an average rating of “Moderate Buy” from the fifteen analysts that are covering the firm, Marketbeat Ratings reports. Two analysts have rated the stock with a hold recommendation, seven have issued a buy recommendation and one has given a strong buy recommendation to the company. The average twelve-month price objective among brokers that have covered the stock in the last year is $203.69.
Several research firms have issued reports on JAZZ. BMO Capital Markets lifted their price target on Jazz Pharmaceuticals from $185.00 to $188.00 and gave the company an “outperform” rating in a research note on Thursday, August 4th. Morgan Stanley raised their price objective on Jazz Pharmaceuticals from $174.00 to $187.00 and gave the company an “equal weight” rating in a report on Thursday, August 4th. HC Wainwright decreased their price objective on Jazz Pharmaceuticals from $210.00 to $204.00 in a report on Friday, August 5th. SVB Leerink raised their price objective on Jazz Pharmaceuticals from $200.00 to $210.00 and gave the company an “outperform” rating in a report on Thursday, August 4th. Finally, StockNews.com upgraded Jazz Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Friday.
Insider Buying and Selling
In related news, CEO Bruce C. Cozadd sold 7,703 shares of Jazz Pharmaceuticals stock in a transaction dated Tuesday, September 6th. The stock was sold at an average price of $153.18, for a total transaction of $1,179,945.54. Following the completion of the transaction, the chief executive officer now owns 353,311 shares in the company, valued at $54,120,178.98. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. In other news, CAO Patricia Carr sold 2,142 shares of the business’s stock in a transaction that occurred on Monday, August 15th. The stock was sold at an average price of $160.06, for a total transaction of $342,848.52. Following the completion of the sale, the chief accounting officer now owns 5,934 shares in the company, valued at $949,796.04. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, CEO Bruce C. Cozadd sold 7,703 shares of the business’s stock in a transaction that occurred on Tuesday, September 6th. The stock was sold at an average price of $153.18, for a total value of $1,179,945.54. Following the sale, the chief executive officer now owns 353,311 shares of the company’s stock, valued at approximately $54,120,178.98. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 48,764 shares of company stock worth $7,619,938. Company insiders own 4.40% of the company’s stock.
Institutional Investors Weigh In On Jazz Pharmaceuticals
Jazz Pharmaceuticals Stock Performance
JAZZ opened at $152.66 on Tuesday. The business’s 50-day moving average price is $156.08 and its two-hundred day moving average price is $154.64. Jazz Pharmaceuticals has a 1 year low of $117.64 and a 1 year high of $169.98. The company has a market capitalization of $9.53 billion, a price-to-earnings ratio of -179.60, a P/E/G ratio of 1.28 and a beta of 0.68. The company has a debt-to-equity ratio of 1.87, a current ratio of 3.67 and a quick ratio of 2.45.
About Jazz Pharmaceuticals
Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various unmet medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of neuroscience, including sleep medicine and movement disorders; and in oncology, including hematologic and solid tumors.
- Get a free copy of the StockNews.com research report on Jazz Pharmaceuticals (JAZZ)
- MarketBeat: Week in Review 9/5 – 9/9
- Prepare For A Record-Setting Quarter For Cyber Security Stocks
- The Auto Market Is Slowly Recovering, These Stocks May Outperform
- Is DocuSign On The Verge Of A Major Reversal?
- Oil and Gas Stocks: A Safe Way to Invest in Renewable Energy
Receive News & Ratings for Jazz Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.